Zimmer Biomet Holdings, Inc (NYSE:ZBH) announced plans to phase out its CPT Hip System by December. The decision comes on the ...

Schwarzenegger joined Zimmer as chief movement officer in November 2024 to promote joint health to wide-ranging communities in the US. The new campaign, called “You’ll Be Back ...

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it is highlighting its diverse portfolio of orthopedic and musculoskeletal innovations at the ...

Combined with Paragon 28 in a deal that is expected to close in the first half of 2025, Zimmer's sports medicine, extremities and trauma segment will be larger than its $2 billion hip business, and ...

The leader in the worldwide market for hip and knee joints is Zimmer Biomet (NYSE: ZBH), with 33% of the market, followed by Stryker with 22%. The UK’s Smith & Nephew is in fourth place with 11%.

we expect our S.E.T. business to be larger than our Hip business, and to grow at a much faster pace," said Ivan Tornos, Zimmer Biomet's President and CEO. Operating margin improved to 19.2% from ...

The firm should move into full commercialization of its Z1 triple taper hip stem in the second half of 2025, leveraging the Z1's versatility and ease of installation. Zimmer Biomet also recently ...

President and Chief Executive Officer at Zimmer Biomet. "We are in the midst of one of the largest innovation cycles in our company's history. Our broad hip reconstruction portfolio combined with ...

Zimmer Biomet posted Q4 adjusted EPS of $2.31, surpassing estimates, with sales of $2.02B, driven by strong knee and hip product growth. The company expects FY25 adjusted EPS of $8.15-$8.35 ...